Kazuoto Hiramoto
Overview
Explore the profile of Kazuoto Hiramoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanaoka H, Kikuchi J, Hiramoto K, Akiyama M, Saito S, Kondo Y, et al.
Mod Rheumatol
. 2024 Oct;
35(2):345-351.
PMID: 39401147
Objectives: To elucidate the effectiveness of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on renal function in patients with rheumatic musculoskeletal diseases complicated by chronic kidney disease (CKD). Methods: We conducted...
2.
Hiramoto K, Saito S, Hanaoka H, Kikuchi J, Fukui H, Hashiguchi A, et al.
Arthritis Rheumatol
. 2024 Sep;
77(3):298-310.
PMID: 39317671
Objective: There is a pressing need to understand the pathogenesis of histologic findings and identify the biomarkers for predicting the histologic severity in lupus nephritis (LN). This study aimed to...
3.
Hiramoto K, Akiyama M, Kaneko Y
Mod Rheumatol
. 2024 Aug;
35(1):94-101.
PMID: 39099100
Objectives: Risk factors for adverse drug reactions (ADRs) associated with prophylactic sulfamethoxazole-trimethoprim (SMX/TMP) in patients with rheumatic and musculoskeletal diseases undergoing immunosuppressive therapy remain unclear; we aimed to identify the...
4.
Kikuchi J, Kondo Y, Kojima S, Kasai S, Sakai Y, Takeshita M, et al.
Immunol Med
. 2024 Jan;
47(2):76-84.
PMID: 38189429
This study aims to elucidate the effectiveness and safety of SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus (SLE). We enrolled uninfected SLE patients who received two vaccine doses...
5.
Hanaoka H, Kikuchi J, Hiramoto K, Akiyama M, Saito S, Kondo Y, et al.
Int J Rheum Dis
. 2023 Aug;
26(10):2007-2013.
PMID: 37540070
Aim: To investigate the impact of high-dose glucocorticoid therapy on sarcopenia in hospitalized patients with rheumatic musculoskeletal diseases (RMDs). Methods: We included patients with RMDs who were hospitalized between 2020...
6.
Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Takeuchi T, et al.
Clin Exp Rheumatol
. 2023 Jan;
41(7):1500-1506.
PMID: 36622105
Objectives: To evaluate the significance of achieving deep remission by induction therapy in lupus nephritis (LN) patients. Methods: We assessed consecutive patients undergoing induction therapy for active LN. Achievement of...
7.
Hanaoka H, Kikuchi J, Hiramoto K, Saito S, Kondo Y, Kaneko Y
Clin Kidney J
. 2022 Jun;
15(7):1373-1378.
PMID: 35756739
Background: We investigated the incidence of chronic kidney disease (CKD) progression and its factors relevant to patients with stable rheumatoid arthritis (RA). Methods: We enrolled consecutive patients with RA who...
8.
Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Kaneko Y, et al.
Rheumatology (Oxford)
. 2022 Jan;
61(9):3777-3791.
PMID: 35015824
Objectives: To demonstrate the significance of the time to attain lupus low disease activity state (LLDAS) after remission induction therapy in patients with severely active SLE. Methods: We enrolled 79...
9.
Hanaoka H, Ishigaki S, Takei H, Hiramoto K, Saito S, Kondo Y, et al.
Int J Rheum Dis
. 2021 Oct;
24(11):1419-1426.
PMID: 34626090
Aim: Pulmonary hypertension (PH) and chronic kidney disease (CKD) are interdependent for their development and exacerbation. We evaluated the effect of PH on CKD progression in patients with connective tissue...